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Porcine reproductive and respiratory syndrome virus (PRRSV) is a significant swine 
pathogen which exhibits considerable sequence diversity. In an attempt to identify highly 
conserved T-cell epitopes contained in proteins of this virus, we examined heptadecamer 
peptides spanning the sequence of the PRRSV nonstructural proteins 9, 10 and 11, all of 
them are highly conserved, for their ability to elicit a recall proliferative and interferon-
gamma response in peripheral blood mononuclear cells obtained from pigs immunized 
against the type-II PRRSV strain FL-12. These studies led to the identification of seven 
peptides, two from each NSP 9 and NSP 10 and, three from NSP 11 that appear to 
contain T-cell epitopes. Comparison of the amino acid sequence of these seven peptide 
sequences to the analogous sequences from a diverse sample of type-II PRRSV strains 
indicated that these sequences are highly conserved and thus contain highly conserved T-
cell epitopes. The identified epitopes may be important in the formulation of 
immunogens to provide broad cross-protection against diverse PRRSV strains.  
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Chapter 1: General Introduction 
Objective 
The identification of T-cell epitopes in PRRSV is sparse and has been limited to 
structural proteins. Two distinct regions on the GP5 amino acid sequence from PRRSV 
genotypes I and II were found to contain T-cell epitopes based on their ability to 
stimulate IFN-γ secreting cells (Diaz et al., 2009). In addition, one report has recently 
reported the identification of four T-cell epitopes located on the membrane (M) protein of 
PRRSV (Wang et al., 2011).  Taken together, these reports illustrate an invigorated 
interest in achieving a more detailed picture of the cell mediated protective immunity 
against PRRSV. Several examples exist, in the case of other highly diverse and variable 
RNA viruses such as hepatitis C virus (HCV) (Martin et al., 2004) and HIV (Gruters et 
al., 2002), indicating that highly conserved, T-cell epitopes are responsible for a broad 
protection based on CMI. Such conserved regions are often detected in nonstructural 
proteins (NSPs) of these RNA viruses that are synthesized early during the life cycle of 
the virus. These NSPs typically constitute structurally constrained, conserved proteins 
involved in replication of the virus. If animals are preferentially immunized against these 
conserved epitopes of NSPs, it is possible that such immunization could result in a highly 
“pan-strain specific” protective immunity. This is the principle applied in the 
development of several multi-epitope vaccines recently reported for “hard-to-immunize” 
RNA viruses such as HCV (Martin et al., 2004) or  HIV (Gruters et al., 2002; Yang et al., 
2002) and also against chronic hepatitis B virus infection (Depla et al., 2008).   
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Accordingly, we selected a subset of PRRSV NSPs based on their functional role in viral 
replication and virulence. The ORF1 (b) region of the PRRSV genome contains the NSPs 
9, 10, 11 and 12 genes. The NSP 9 is the viral RNA-dependent RNA polymerase (RdRp) 
required for genome replication and transcription and the NSP 10 encodes for helicase 
function (Fang and Snijder, 2010). The main criteria used to select NSP 9, NSP 10 and 
NSP 11 for this study was their highly conserved nature which is consistent throughout 
the North American PRRSV strains, thus constituting good candidates for the 
identification of T-cell epitope that could provide target antigens capable of eliciting 
cross-protective immunity against PRRSV. To achieve this goal, overlapping 
heptadecapeptides spanning the entire length of the PRRSV NSP 9, NSP 10 and NSP 11 
were screened respectively using T-cell proliferation and IFN-γ ELISpot assays. Herein 
we report the identification of T-cell epitopes mapping to these PRRSV NSPs. Two 
distinct regions each in NSP 9 and NSP 10 and, three distinct regions in NSP 11 were 
identified as putative T-cell epitopes. As expected, these epitopes were found to be highly 
conserved among thirty-four North American PRRSV type-II sequences. Moreover, 
sixty-five additional sequences analyzed to detect the conservation of those T-cell 
epitopes also proved positive with a high percentage of conservation throughout the 
North American PRRSV strain. 
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Chapter 2: Literature Review 
Porcine Reproductive and Respiratory Syndrome Disease 
Porcine reproductive and respiratory syndrome (PPRS) leads to respiratory disorder in 
young pigs. It also causes severe reproductive failure and late abortions in sows. The 
disease was first reported in 1987 in North America, and the causative agent was isolated 
and characterized for the first time in Europe in 1991(Wensvoort et al., 1991) and one 
year later in the United States of America (Collins et al., 1992). PRRS has now emerged 
in the swine industries worldwide and has caused significant economic loss in the pork 
industry worldwide (Neumann et al., 2005). The causative agent PRRS virus (PRRSV) is 
a member of the family Arteriviridae which also comprises of other viruses such as 
Equine Arteritis Virus (EAV), mouse lactate dehydrogenase elevating virus (LDV), and 
Simian Hemorrhagic Fever Virus (SHFV) (Cavanagh, 1997). 
PRRSV is also known as “Blue-Ear Pig” disease which is primarily transmitted via 
aerosols. It affects mostly young sows and boars (Rossow, 1998). The important factors 
responsible for the PRRSV infection in the matured pigs rely on the type of PRRS viral 
strain, gestation period, breed, gender and immune status of the PRRSV infected sows. 
PRRSV infected pregnant sows show clinical manifestations which include fever, 
anorexia, lymphadenopathy, labored respiration, gross and microscopic lesions in the 
lung, and reproductive failure characterized by delivery of weak/stillborn piglets 
autolysed fetuses (Christianson et al., 1992; Hopper et al., 1992; Rossow et al., 1994; 
Terpstra et al., 1991). PRRSV infection in neonatal pigs develops variable clinical signs 
characterized by severe dyspnea and tachypnea (Cooper et al., 1995; Hopper et al., 1992; 
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Rossow et al., 1994; Rossow et al., 1995; Wensvoort et al., 1991). Death rate of the 
PRRSV infected neonatal pigs exceeds up to 100% (Rossow, 1998).  
One of the important features of PRRSV infection is prolonged viremia in the infected 
pigs and this may result in continuous shedding of virus for longer periods without 
entering a latent stage. Tonsils, lungs and lymphoid organs are the major source of viral 
RNA during the persistence of PRRSV infection in the infected pigs (Lamontagne et al., 
2003). Also, PRRSV RNA has been detected by RT-PCR in the semen of boars 
evidenced in vivo at 92 days post infection (d.p.i) (Christopherhennings et al., 1995). In 
postnatally infected pigs persistence of PRRSV has been reported for up to 150 days, 
while naturally infected pigs contained virus even up to 210 days(Cho and Dee, 2006). 
Porcine Reproductive and Respiratory Syndrome Virus  
PRRSV is a small, enveloped and cytolytic virus with a size of 50-65 nm.  This positive-
sense single stranded RNA virus carries a methylated cap at the 5’ end and a 
polyadenylated tail at the 3’ end of its genome. PRRSV belongs to order Nidovirales, 
family Arteriviridae, genus Arterivirus and its genomic length is about 15.4 kilobase 
(Cavanagh, 1997; Conzelmann et al., 1993; Wu et al., 2001). It contains 9 open reading 
frames (ORFs) among which ORF1a and 1b comprise about 80% of the genome and 
encode for two polyproteins which, after translation, are proteolytically cleaved into 14 
nonstructural proteins (NSPs), e.g., NSP1α, NSP1β and NSP2 to NSP12. Both NSP 9, 
which encodes the viral RNA-dependent RNA polymerase (RdRp) and NSP 10, which 
encodes a helicase, are responsible for the viral genome replication and transcription.  
The RdRp domain is found in the C-terminal portion of replicase subunit, NSP 9, which 
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contains an additional upstream domain of unknown function. PRRSV RNA helicases are 
a diverse class of enzymes that uses ATP hydrolysis to unwind RNA duplexes in a 5’-to-
3’ direction in vitro. Like RdRp domain, helicase is part of a larger replicase subunit, 
NSP 10, which also contains an N-terminal predicted zinc-binding domain comprising of 
highly conserved 13 Cys and His residues. This particular domain can prove critical for 
the in vitro ATPase and helicase activities of the protein. In addition to the core viral 
enzymes (NSP 9 and NSP 10), the Nidovirus endoribonuclease (NendoU) domain has 
been identified in NSP 11 and is N-terminally fused to another domain of unknown 
function. It has been evidenced through reverse genetics that this particular domain of 
NSP 11 plays an important role in the replicative cycle of all Arteriviruses (Bautista et 
al., 2002; Fang and Snijder, 2010). Nedialkova et al has shown that recombinant PRRSV 
NSP 11 exhibited broad substrate specificity in vitro (Fang and Snijder, 2010; 
Nedialkova et al., 2009). It has also been demonstrated that the NendoU knockout 
mutants remained capable of RNA synthesis that helped in the prediction that this 
enzyme may not function in a Nidovirus-specific step of viral synthesis but rather targets 
unknown cellular substrates(Fang and Snijder, 2010). ORFs 2a, 2b and 3-7 located at the 
3’ end of the viral genome undergo posttranslational cleavage to produce PRRSV 
structural proteins (Dea et al., 1996; Meulenberg et al., 1995; Wu et al., 2001). The 
structural proteins are expressed from the 3’ end nested set of sub-genomic m RNA Abs 
sharing the common leader sequence at the 5’ terminus (Meulenberg, 2000; Snijder and 
Meulenberg, 1998). Glycoprotein 5 (GP5), membrane (M) and nucleoprotein (N) 
encoded by ORFs 5-7, respectively, are known to be the major components viral particles 
(Dea et al., 2000). The N protein interacts with viral genome to form the nucleocapsid. M 
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interacts with GP5 to form a heterodimer which is essential for viral assembly since viral 
particles are not released in the absence of either GP5 or M protein (Mardassi et al., 1996; 
Wissink et al., 2005). The minor proteins in viral particles include ORF 2a, 3 and 4 and 
they encode for GP2a, GP3 and GP4, respectively. These proteins interact with each 
other and are assembled into the virion as a multiplex complex which is also involved in 
viral infectivity (Wissink et al., 2005). ORF2b, otherwise called as envelope protein (E), 
is embedded within the ORF2a (Wu et al., 2001). 
In spite of the route of entry, productive infection occurs predominantly in alveolar 
macrophages of the lung (Murtaugh et al., 2002). In vitro studies with the virus infection 
in these cells have shown their ability to grow in primary cultures of alveolar lung 
macrophages. PRRSV has a strong restricted cell tropism for certain subpopulations of 
swine monocyte or, macrophage lineage, notably pulmonary intravascular macrophages, 
subsets of macrophages in lymph nodes and spleen, and intravascular macrophages of the 
placenta and umbilical cord (Duan et al., 1997; Lawson et al., 1997). In experimentally 
infected boars, PRRSV can be detected by PCR in semen samples at 92 d.p.i 
(Christopher-Hennings et al., 1995; Christopherhennings et al., 1995). Experimental 
studies have shown that subclinical PRRSV infection can persist in the animals. Thus, 
persistent infection of PRRSV plays a major role in PRRSV survival and transmission, 
and will likely pose an obstruction in the PRRS control programs (Bilodeau et al., 1994; 
Wills et al., 1997). 
PRRSV grows well in the African monkey kidney cell MA-104 and its derivatives 
MARC-145, CL-2621 and CRL11171 (Benfield et al., 1992; Collins et al., 1992; Kim et 
al., 1993; Meng et al., 1994; Meng et al., 1996). They can also be grown in porcine 
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alveolar macrophages (PAM) cultures (Wensvoort, 1993; Wensvoort et al., 1991). Swine 
testis (ST) cells were also reported to support PRRSV replication (Plana et al., 1992). 
Receptor-mediated endocytosis helps the PRRSV to enter into the host cells (Kreutz and 
Ackermann, 1996; Nauwynck et al., 1999). Some strains of PRRSV do not propagate in 
all the cell lines showing variations in their susceptibilities as a result, this indicates the 
existence of PRRSV variants. Thus, both PAM and other cell lines should be used when 
attempting virus isolation from clinical samples. The PRRSV virion after attachment with 
the host cell receptors enters into the cells in a clathrin-dependent manner. The viral 
genomic RNA transfected in the BHK-21 cells lead to the production of infectious virus.  
Interestingly, cell receptors play a major role as a determinant in PRRSV cell-tropism. 
(Meulenberg et al., 1998; Nielsen et al., 2003).  
Two independent PRRSV receptors heparin sulfate and porcine sialoadhesin (PoSn) have 
been identified in PAM. On the alveolar macrophages, the viral protein heterodimer GP5-
M interacts with the porcine cell surface receptor porcine sialoadhesin. However, this 
interaction prevents virus entry into the cells irrespective of the binding of viral particles 
to the cell surface receptors (Delputte et al., 2005; Delputte et al., 2002). In the meantime, 
sialoadhesin is responsible for both viral attachment and internalization. During 
uncoating of the virus, it functions together with CD163 (Delputte et al., 2005; Duan et 
al., 1998; Van Gorp et al., 2008; Vanderheijden et al., 2003). Minimal levels of PoSn 
expression by the non-activated monocytes may play important role in susceptibility to 
PRRSV infection (Kimman et al., 2009). 
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Genetic and Antigenic diversity among various PRRSV strains 
PRRSV has been clinically, genetically and antigenically divided into two types which 
include European (EU-type-I) and North American (NA-type-II) (Mardassi et al., 1994; 
Meng, 2000; Meng et al., 1994; Meng et al., 1995b; Morozov et al., 1995; Murtaugh et 
al., 1995). Both of them cause very similar clinical signs in swine irrespective of their 
genetic and serological differences. 
Genetic diversity 
PRRSV is genetically heterogeneous by nature (Meng, 2000). The two genotypes 
resemble 60% to each other based on their overall nucleotide homology although their 
biological characteristics are very similar (Kim and Yoon, 2008). The relative nucleotide 
sequence identity between the US isolates and Lelystad is 45.7% in ORF1b, 65-67% in 
ORF2, 61-64% in ORF3, 63-66% in ORF4, and 61-63% in ORF5 (Meng et al., 1995a; 
Meng et al., 1995b). ORFs 6 and 7 genes are relatively conserved among the US isolates 
or among the EU isolates, but extensive genetic variation was observed in the ORFs 6 
and 7 genes between EU and US isolates (Meng et al., 1995a). It has been demonstrated 
by certain experimental analysis of the nucleotide sequence of ORFs 2-7 of 10 US 
PRRSV isolates that the genetic distance ranges from 2.5-7.9% and is about 35% 
between LV and the US isolates (Kapur et al., 1996). GP5, the major envelope protein is 
highly variable and is only 50-55% identical between the two genotypes (Mardassi et al., 
1995; Meng et al., 1995b; Nelsen et al., 1999). This variability is caused due to greater 
induction of neutralizing antibodies (NAbs) which causes exposure to selective antibody 
pressure. The ORF1 genomic sequence also differs extensively between the US and the 
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EU strains by 55% nucleotide sequence identity (Allende et al., 1999; Nelsen et al., 
1999). ORF1b is more conserved than ORF1a and shares 63% nucleotide sequence 
identity with that of LV (Meng, 2000). The pathogenic NA PRRSV isolate 16244B has 
similar sequence homology with the LV with only 63.4% nucleotide identity. ORF1a 
polyprotein containing the non-structural part has major differences which shared 47% 
amino acid identity over 2503 residues of the six NSPs encoded. The greatest diversity is 
found in the NSP2 genome. About 32% amino acid identity is shared with the NSP2 
region of LV. It also contains 120 additional amino acids in the central regions. NSPs 
encoded by the 5’-proximal and central regions of ORF1b have 66-75% amino acid 
identity. In addition, the ORF1a-1b frame shift region of 16244b has 98% nucleotide 
identity with LV (Allende et al., 1999; Meng, 2000).  
Current studies have shown that EU-PRRSV is also found in other parts of the world 
such as Canada (Dewey et al., 2000). Meanwhile, type-II PRRSV has also been found in 
European region via introduction of live vaccine (Nielsen et al., 2001; Nielsen et al., 
2002; Storgaard et al., 1999). It has been noticed that EU-like PRRSV isolates have 
slowly emerged in the US herds (Fang et al., 2007; Ropp et al., 2004). The remarkable 
feature in EU-PRRSV which differentiates it from the NA-PRRSV is the deletion of 51 
nucleotide in its NSP2 region (Fang et al., 2007). PRRSV genetic heterogeneity has 
increased over time and co-circulation of different variants and their maintenance may 
contribute to heterogeneity. This can evident from the analysis of the nucleotide sequence 
similarity that has decreased up to 4.4% range in between the years 1995 and 2000 
(Prieto et al., 2009). 
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The concept of quasispecies variation was demonstrated by sequence analysis of various 
PRRSV strains which highlighted the strategies of PRRSV infection spread among 
interspecies (Goldberg et al., 2003). It has also been reported that there are evidence for 
quasispecies evolution and emergence of a virus subpopulation during utero infection of 
pigs with a PRRSV isolate (Rowland et al., 1999). The importance of having a 
quasispecies population during virus infection will affect vaccine efficacy and may lead 
to vaccine failure (Domingo et al., 1998; Domingo and Holland, 1992; Duarte et al., 
1994). Therefore, future investigation in this regard can prove beneficial in the field o 
PRRSV immunology. 
Other important factors leading to the genetic divergence in PRRSV includes the lack of 
proof-reading activities of RdRp. RNA recombination is also another serious factor 
leading to the PRRSV polymorphism (Meng, 2000). Recombination of viral particles 
containing chimeric ORF3 and ORF4 proteins of PRRSV genome were identified during 
co-infection of two PRRSV isolates in MA-104 cells which showed an estimated 
frequency of recombination from <2 to 10%. Moreover, sequence analyses of various 
field isolates of PRRSV have revealed that RNA recombination of PRRSV can also occur 
in nature(Yuan et al., 1999). 
Antigenic Variation 
Antigenic variations among various isolates of PRRSV have been well documented 
(Meng, 2000). It has been reported about the differential activity of the monoclonal 
antibodies (MAbs) using the two genetic types of PRRSV, EU- and NA- types. Two 
MAbs VO17 and EP147 to N protein recognized a conserved epitope in US and EU-
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PRRSV isolates. The N-protein MAb SDOW17 works as a common MAb to both NA 
and EU-PRRSV isolates indicating the presence of a common conserved epitope (Nelson 
et al., 1993).  However, four other MAbs of PRRSV N-protein responded to NA-PRRSV, 
confirming their strain-specificity (Nelson et al., 1993). Six MAbs raised against British 
isolate of PRRSV recognized EU isolates but did not react with US isolates (Drew et al., 
1995). Five anti-GP5 MAbs from a Canadian isolate were unable to react with LV 
(Pirzadeh and Dea, 1997). The reactivity of MAbs against GP3, GP4 and N proteins with 
EU- and US-PRRSV isolates revealed antigenic differences both within the isolate as 
well as between the isolates (Katz et al., 1995; Wieczorek-Krohmer et al., 1996).  
The degree of antigenic variation within each PRRSV type is highly considered during 
the design of future vaccines. A multivalent vaccine comprising of multiple antigenically 
distinct strains of PRRSV can prove as the most promising candidate for the next 
generation of vaccines (Meng, 2000).  
Immune Response 
Development of a weak and delayed protective immunity against PRRSV infection leads 
to prolonged acute and persistent infection in pigs. The acute post-infection is followed 
by the presence of clinical symptoms and abundant replication in target cells such as 
alveolar macrophages. Acute post-infection is characterized by high viral load in tissues 
and by the presence of cell-free (serum associated) viremia for one month. The persistent 
phase of PRRSV involves low level of viral replication. 100% viral clearance was seen in 
at least more than 150 days post-infection. A period of two months post-infection for 
effective contagion to other animals has been seen early after exposure a vigorous anti-
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PRRSV antibody response at 7-9 days post-infection was detected by ELISA. Antibodies 
with PRRSV-neutralizing activity appear only at later post-infection times (≥ 4 weeks), 
leading to polygonal B-cell activation. Presence of total antibodies in serum during early 
post-infection viremic phase of PRRSV infection indicates about the inability of 
antibodies to play a role in protection against PRRSV infection. Anti-PRRSV antibodies 
constitute a non-protective but deleterious response. Due to slow, irregular appearance of 
PRRSV-NA after PRRSV exposure, it was able to prevent the appearance of viremia. 
Infected pigs develop a T-cell mediated response at 4 weeks PI indicating a CD4 T-cell 
response. Specific IFN-γ production by T-cells (CTL specific response) showed a delay 
in the response similar to the one observed with NA. Mostly infected pigs shed viral 
infection at approximately 3-4 months of post-infection. Therefore, it is difficult to gain a 
complete solid protection against PRRS infection (Lopez Fuertes et al., 1999; Lopez and 
Osorio, 2004; Meier et al., 2003). Moreover, very little information is known about the 
PRRSV structural and nonstructural proteins that can provide protective immunity 
against PRRSV infection. 
Innate immunity 
Host innate immunity exhibits a crucial role in the PRRSV immunology. Type-I 
interferons (e.g., IFN-α/β) display innate protection against PRRSV infection (Seth et al., 
2006). Various experimental studies have reported that PRRSV is sensitive to the 
antiviral effects of type-I IFN (Buddaert et al., 1998; Lee et al., 2004; Miller et al., 2004). 
In vitro studies have shown that upon pretreatment of PAM culture with porcine IFN-α 
prior to PRRSV infection has resulted in significant reduction in virus titer (Albina et al., 
1998; Buddaert et al., 1998; Lee et al., 2004). The sensitivity of PRRSV to IFN effects is 
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PRRSV isolate-dependent(Lee et al., 2004). Several studies have revealed that IFN-α 
helps in the clearance of viral activity in infected pigs. PRRSV infection alone is unable 
to IFN-α. Interestingly, pigs which were infected with Corona virus prior to PRRSV 
infection, resulted in potential induction of IFN-α, thereby, deliberately reducing viral 
titers (Buddaert et al., 1998). It has also been evidenced that PRRSV is a poor inducer of 
type-I IFNs (Albina et al., 1998; Lee et al., 2004; Miller et al., 2004). Moreover, it has 
been suggested that PRRSV may actively suppress type-I IFN production (Albina et al., 
1998). PRRSV infection in pigs rarely elicit IFN-α in their sera and lung secretions 
(Albina et al., 1998). In vitro, PRRSV infection to PAM cells do not show marked 
induction in the IFN-α production (Albina et al., 1998; Lee et al., 2004). Also, MARC-
145 infected with PRRSV has shown alteration in the production of both IFN-α/β m RNA 
Abs in response to double stranded RNA stimulation (Miller et al., 2004). The viral 
particles important for the potent elicitation of type-I interferons have not been 
indentified clearly. Recent works have been published to show that few PRRSV proteins 
such as NSP1, NSP2, NSP4, NSP 11 and N-protein are involved in IFN-β production 
(Beura et al.). It has also been proved that PRRSV infection inhibited function of IFN-β 
promoter stimulator 1 (IPS-1) molecule of the retinoic acid –inducible gene I (RIG-I) or 
TLR-independent dsRNA signaling pathway which resulted in the inhibition of synthetic 
dsRNA-induced IFN-β production and IRF3 nuclear translocation (Luo et al., 2008). An 
intriguing observation is that the production of IFN-γ response in swine serum lasts 
approximately for 3 weeks (Wesley et al., 2006). Serum levels with increased amount of 
viral load and inhibition of PRRSV replication by IFN-γ lead to the conclusion that IFN-γ 
may have a crucial role in the PRRS disease (Bautista and Molitor, 1999; Gaudreault et 
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al., 2009; Loving et al., 2008). Generally early production of IFN-γ could be due to the 
activation of natural killer (NK) cells and alveolar macrophages. These pathways have 
not been identified yet in PRRSV. 
Acquired immunity 
The delayed immune response developed for protection against viral infection is a 
debated issue. It takes at least 3 months of time period to develop immunity against 
natural infection. Moreover, this does not confer a solid protection to prevent re-
infection, especially caused by heterologous PRRSV strains (Murtaugh et al., 2002; 
Zuckermann et al., 2007). Experimental studies have shown that gilts infected with an 
US-PRRSV type isolate and challenged with EU-PRRSV isotype (Lelystad virus) late in 
gestation period provided partial protection against the transplacental infection, whereas 
all the gilts challenged with the homologous virus were completely protected (Lager et 
al., 1999). These studies provided information about the existence of the partial 
heterologous protection and also indicate that common epitopes are likely involved in 
protection against EU- and US-PRRSV strains. As a result, it has become important to 
understand the acquired immunity in spite of a broad genetic and antigenic variation of 
circulating strains of PRRSV which can help to induce IFN-γ to provide a protective 
immunity against PRRSV infection. Moreover, it has been suggested by Diaz et al., that 
the different capacity of PRRSV strains to induce protective immunity depends on their 
different capacity to induce a strong cellular, in particular IFN-γ, immune response(Diaz 
et al., 2006). 
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Humoral immunity 
An important aspect of PRRSV infection is the delayed development of NAbs. PRRSV-
specific antibodies begin to appear in the infected pigs as early as 7-10 d.p.i with a low 
viral titer (Loemba et al., 1996; Plagemann, 2006). The main feature of the onset of 
humoral immune response consists of early production of low leveled non-NAbs 
followed by delayed NAbs between 2-4 weeks PI (Labarque et al., 2004; Loemba et al., 
1996). It has been demonstrated that there may be a high induction of NAbs and virus in 
vivo, but on experimental basis both NAbs and non-NAbs lead to PRRSV replication in 
macrophages. As a result, these antibodies can bind to the virus and internalize the viral 
particles into macrophages (Diaz et al., 2006). In vitro studies have demonstrated PAM 
and MARC-145 cells are prone to secondary PRRSV infection even after the 
development of early antibodies from the first infection (Nelson et al., 1994; Yoon et al., 
1994; Yoon et al., 1995). Antibodies which are passively transferred from pregnant sows 
to the off springs provide protection against PRRSV infection and help to block 
transplacental PRRSV infection (Lopez et al., 2007; Osorio et al., 2002). This shows 
antibodies are important in protecting swine against re-infection with PRRSV. However, 
addition of NAbs helped in the suppression of viral infectivity in the already infected 
PAM and MARC-15 cells. This was achieved by blocking viral attachment and 
internalization (Delputte et al., 2004). Generally, NAb were first detected in serum at 
about 4 weeks PI (Lopez and Osorio, 2004; Mateu and Diaz, 2008). Thus, inefficiency of 
NAbs and early antibodies towards developing a solid protection confirmed that 
antibodies alone cannot protect the pigs against PRRSV infection. It was further 
confirmed from experimental studies that induction of viral infection and replication is 
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further supported by the antibody production. NAbs pass from mother to their off springs 
via colostrums and milk to provide protection against PRRSV infection (Yoon et al., 
1996). Importantly, there is a chance of NAbs getting transferred from sows to their 
offspring maternally through the colostrum and milk. Thus, it provides sterilized 
immunity in the new-born piglets. Labarque et al., from his findings has suggested one 
most important role of NAbs in virus clearance related with the clearance of PRRSV 
from the lungs of infected pigs and the appearance of neutralizing antibodies in sera and 
bronchoalveolar fluids (Labarque et al., 2004).  
PRRSV nucleocapsid protein carries the highest immunogenic properties among all the 
PRRSV proteins. High levels of anti-N antibodies could be detected at 7 d.p.i, but these 
do not provide neutralizing property and hence, do not correlate with protection against 
PRRSV infection. However, these are unable to neutralize the virus. It has been reported 
that viral epitopes capable of inducing NAbs resides on the GP2a, GP3, GP4, GP5 and M 
proteins (Meulenberg et al., 1997; Ostrowski et al., 2002; Plagemann et al., 2002; Yang et 
al., 2000). Among these, NAbs against GP5 of both European and North American 
PRRSV happen to be most relevant for protection as major neutralization epitope of 
PRRSV are located in the middle of the GP5 ectodomain (Plagemann et al., 2002). The 
neutralizing activity of MAbs against GP5 has been known to show stronger activity than 
that of antibodies to the GP4 (Weiland et al., 1999). GP5-based neutralizing epitope of 
NA-PRRSV denoted as Epitope B is highly conserved (Ostrowski et al., 2002; 
Plagemann, 2004). An additional immunodominant non-neutralizing decoy epitope, 
epitope A, present in the upstream of the epitope B interferes with the immune response 
to epitope B (Fang et al., 2006). It has been shown that the proximity of epitopes A and B 
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is a compulsory requirement in delayed NAb response (Fang et al., 2006). The flanking 
N-linked glycosylation sites on both sides of the epitope B exhibits poor immunogenicity 
of the epitope B. Hence, it leads to an early and high induction of NAbs response as 
compared to the wild-type virus (Mateu et al., 2006). 
It has also been reported that the M protein contain two neutralizing epitopes. It has been 
shown that the GP5-M interaction has been used for the construction of a DNA vaccine 
but NAbs titers induced by this vaccination protocol were low (Jiang et al., 2006). 
However, GP3 and M protein NAbs remain unidentified yet. Interestingly, the 
neutralizing ability of GP3-specific antibodies has been mentioned due to its 
characterization as a NSP in some NA-PRRSV isolates as well as a structural protein in 
some EU-PRRS isolates (Meulenberg and Petersen-den Besten, 1996). Also, EU-PRRSV 
contains a neutralizing epitope in its ORF4 region (Vanhee et al.).  
Cell-mediated immunity 
Cellular mediated immunity (CMI) plays an important role in PRRSV immunology.  
Previous studies have shown that pigs recovering from experimental PRRSV infection 
develop strong lymphocyte proliferative and NA responses after four weeks PI (Bautista 
and Molitor, 1997; Lopez Fuertes et al., 1999). T-cell responses were mainly categorized 
by type-I cytokine expression phenotype with IFN-γ as the major cytokine and, to a lesser 
extent, IL-2 (Lopez Fuertes et al., 1999). These kinds of cytokine expression are 
generally identified between 4-12 weeks PI (Bautista and Molitor, 1997; Lopez Fuertes et 
al., 1999). Post-vaccination with US-PRRSV modified live vaccine have led to the virus-
specific IFN-γ secreting cells which appeared first in the third week post-vaccination and 
18 
 
increased the number of peripheral blood mononuclear cells (PBMCs) at 48 weeks post-
vaccination (Meier et al., 2003). The double positive cells (CD4+CD8+) present in the 
porcine immune system are responsible for IFN-γ secretion (Meier et al., 2003). An 
identical immune response with delayed development of PRRSV-specific IFN-γ secreting 
cells was evident after infection or vaccination with European strains of PRRSV (Diaz et 
al., 2005; Diaz et al., 2006). However, a live attenuated PRRSV vaccine that induced 
high IFN-γ secreting cell frequencies protected pigs against viremia. IL-10 levels have 
also been observed to inversely correlate with the IFN-γ responses. These results include 
the involvement of a strong T-cell immunity, IFN-γ and IL-10 in the development of 
immunity against PRRSV(Diaz et al., 2006). This indicates towards the switching over of 
the immune response from Th1-Th2-mediated immune response. However, GP2(a/b), 
GP3, GP4, GP5, M and N proteins of PRRSV were examined individually to validate 
their capability to induce T-cell proliferation. Upon individual expression of these ORFs 
using vaccinia virus system it was revealed that the M protein was the strongest inducer 
of proliferation (Bautista et al., 1999; Jiang et al., 2007a; Jiang et al., 2007b; Lopez 
Fuertes et al., 1999). There is a possibility that PRRSV may interfere with correct antigen 
presentation and activation of T lymphocytes. PRRSV caused down-regulation of the 
expression of major histocompatibility complex (MHC)-I in dendritic cells (DCs), in 
spite of its correlation with the impaired proliferative responses in the mixed leukocyte 
reaction (Loving et al., 2007). Expression of MHC-I, MHC-II and CD14 was down-
regulated in monocyte-derived DCs infected with infectious PRRSV (Wang et al., 2007). 
Decreased proliferative responses were observed when infected DCs were used with 
syngeneic or allogeneic lymphocytes. This again suggests that infected DCs present 
19 
 
antigens less efficiently (Wang et al., 2007).  By altering the cytokine patterns of 
macrophages and dendritic cells, as well as by modifying the expression of molecules 
involved in antigen presentation PRRSV can down-regulate the innate immune response 
(Mateu and Diaz, 2008). It has been noted that PBMCs isolated from infected pigs upon 
treatment with CD4 and MHC class-II antibodies tend to reduce around 85% in the T-cell 
proliferation (Lopez Fuertes et al., 1999). This led to a conclusive remark that CD4+ T-
cells are specifically induced during T-cell proliferation. In fact, these infected PBMCs 
showed greater IL-2 and IFN-γ response in comparison to IL-4 and IL-10. This 
demonstrates that the CD4+ T-cells predominantly function in CMI response (Lopez 
Fuertes et al., 1999).  
ELISpot technology is a widely used assay to detect the CMI response against PRRSV 
infection.  These can be well predicted by estimating the IFN-γ secreting cells (IFN-γ-
SC) in the PBMCs at 14 d.p.i. The frequency of IFN-γ-SC increases to its maximal levels 
at 28 d.p.i and then slowly declines (Diaz et al., 2005; Diaz et al., 2006; Xiao et al., 2004; 
Zuckermann et al., 2007). Alternate reports have conveyed that IFN-γ-SC remain 
undetected until 8-10 weeks PI. But its frequency gradually increases by 48 weeks PI and 
remains stable until 690 d.p.i (Meier et al., 2003). However, the ability of PRRSV to 
induce IFN-γ-SC is comparatively low and delayed (Meier et al., 2003).  
For most of the proteins T-cell epitopes have not yet been identified at amino acid level. 
Consequently it is unknown whether conserved T-cell epitopes might provide cross-
protection against different PRRSV strains. Determination of T-cell epitopes is an 
expensive and cumbersome task due to the lack of a systematic approach based on the 
synthesis and testing of large sets of overlapping peptides. Various strategies have been 
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used to determine the PRRSV T-cell epitopes only in structural proteins. ELISpot assay 
has been used recently by Vashisht et al., which helped them to identify two distinct 
regions (amino acid residues 117-131 and 149-163) on GP5 of the North American 
genotype of PRRSV that appeared to contain immunodominant T-cell epitopes (Vashisht 
et al., 2008). Moreover, bioinformatics approach along with the ELISpot assay has helped 
Diaz et al., group to detect two distinct regions on the GP5 amino acid sequence from 
PRRSV genotypes I and II (Diaz et al., 2009). In addition, one report has recently 
reported the identification of four T-cell epitopes located on the membrane (M) protein of 
PRRSV(Wang et al., 2011). Taken together, these reports illustrate an invigorated interest 
in achieving a more detailed picture of the cell mediated protective immunity against 
PRRSV. Several examples exist, in the case of other highly diverse and variable RNA 
viruses such as hepatitis C virus (HCV) (Martin et al., 2004) and HIV (Gruters et al., 
2002), indicating that highly conserved, T-cell epitopes are responsible for a broad 
protection based on CMI. Such conserved regions are often present in the NSPs of these 
RNA viruses that are synthesized early during the life cycle of the virus. These NSPs 
typically constitute structurally constrained, conserved proteins involved in replication of 
the virus. Thus, it has become essential to determine T-cell epitopes in those proteins and 
vaccinate the PRRSV infected pigs with those conserved epitopes to develop “pan-strain 
specific” protective immunity.     
 Vaccine Development against PRRS disease 
Multiple vaccines against PRRSV infection are available commercially available. These 
include inactivated-vaccines, modified-live vaccines, DNA vaccines and recombinant 
DNA vector vaccines (Kimman et al., 2009). Current vaccines against PRRSV have 
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several drawbacks. Modified live vaccines protect against homologous isolates but 
generally have a limited effect against, challenge with heterologous viruses. Live PRRSV 
vaccines provide partial protection against clinical disease but do not prevent infection. 
Also, it can revert to virulence. Attenuated vaccines work similar to natural PRRSV 
infection with low NA production. Killed vaccines have proved less effective in 
prevention of both infection and disease. NA epitopes have also been developed to 
generate new vaccines for protective response. At the same time, onset of IFN-γ inducing 
CTL-response as well as CD4 T helper immune response as delayed immune response 
may provide protective immunity. Both NA and virus-specific IFN-γ producing cells 
have played important role in the designing of vaccines (Lopez and Osorio, 2004; Osorio 
et al., 2002; Zuckermann et al., 2007). It has been reported that PRRSV-NA helps in the 
prevention of infection of pregnant sows as well as transplacental infection (Osorio et al., 
2002). A killed vaccine inducing NAbs failed to protect pigs against an in vivo challenge 
with the virus (Zuckermann et al., 2007). These pigs displayed a secondary neutralizing 
antibody response upon challenge inoculation, thus suggesting the inefficiency of recall 
response to provide full protection. 
 The inactivated-vaccines contain adjuvant. Killed-vaccine has failed to provide cross-
protection against PRRSV infection. This was highly evident from the clinical signs, 
reproductive failure, constant magnitude of viremia in semen among homologous strains 
and congenital infection in the off springs. Also it remained unaffected in the sows and 
boars (Scortti et al., 2007). Administration of killed-vaccine in boars did not change and 
magnitude of viremia and shedding of virus in semen even against homologous challenge 
(Nielsen et al., 1997).  
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Modified-live vaccines (MLVs) have shown greater effectiveness in reducing disease 
probability, and also during viremia and virus shedding. Protection by modified live 
vaccines has shown solid protection against clinical disease induced by homologous 
infection while the level of protection induced by MLVs against heterologous strains is 
variable and substandard (Meng, 2000).  However, MLVs were incapable to provide long 
term protection against PRRSV infection (Christopher-Hennings et al., 1997; Diaz et al., 
2006; Labarque et al., 2004; Martelli et al., 2007; Okuda et al., 2008; Prieto et al., 2008; 
Zuckermann et al., 2007). Simultaneously, MLVs prepared by targeting GP5 provided 
complete protection against PRRSV (Labarque et al., 2004). It has been examined with 
the so-called therapeutic vaccine intervention that it was unable to eliminate wild-type 
PRRSV, but it significantly reduced the number of pigs persistently infected with a 
homologous strain, but not pigs persistently infected with a heterologous strain (Cano et 
al., 2007a; Cano et al., 2007b). Live-attenuated PRRSV vaccine (Ingelvac PRRS MLV
R
) 
has been examined to check the adjuvant effects of several adjuvants on its protective 
efficacy against PRRSV infection. Co-administration of IL-12 significantly helps in the 
induction of the cell-mediated immune response to MLV vaccine as compared to MLV 
alone (Charerntantanakul et al., 2006).  
Various recombinant virus vector systems such as live attenuated vaccine-based Pseudo 
rabies virus recombinant (strain Bartha)(Qiu et al., 2005), replication-defective 
adenovirus recombinants(Jiang et al., 2008) and Mycobacterium tuberculosis strain 
BCG(Bastos et al., 2004) has been used against PRRSV infection to induce immunity to 
PRRSV. All the above data available so far suggest that all structural proteins of the virus 
are essential for the production of infectious virus. Role of nonstructural proteins (NSPs) 
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in the field of PRRS immunology has not been implemented yet. Their functional and 
structural constraints can make many changes in the development of vaccine against 
PRRSV. As NSPs are highly conserved among the various strains of the homologous as 
well as heterologous genotypes, they can prove beneficial in cell-mediated immune 
response. A safe, universal and efficient vaccine can provide a core protection to treat 
PRRS affected pigs. The first priority depends on the detection of B- and T-cell epitopes 
involved in the development of protective immunity. Neutralizing epitopes have been 
established definitively but very little is known about T-cell epitopes, although T-cell 
responses to individual PRRSV polypeptides have been reported in virus-infected 
animals. The most important criteria performing this kind of experiment involve the 
genome conservation of those epitopes in both European and American strains 
(heterologous protection) as well as among the homologous strain (within American or, 
European) of PRRSV(Bautista et al., 1999). The next important requirement is the 
involvement of the components of the virion or viral genome responsible for viral down-
regulation or modulation of the swine immune system. The importance of a universal 
vaccine not only includes immunological properties but, also the characteristics of the 
strain, relationship between the immunopathological properties and genetic diversity 
matters a lot (Mateu and Diaz, 2008). The third criteria incorporate the avoidance of the 
possibilities of reversion of a viral strain in to virulence and also minimal transmission of 
the vaccine strain between pigs. The obvious way to avoid this kind of possibilities is by 
using non-replicating vaccines which are again questionable on their ability to induce 
NAbs and adequate cell-mediated immune responses (Zuckermann et al., 2007). Subunit 
or vector-based vaccines and inclusion of adjuvant can take active replacement on these 
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parameters. The last important thing is the development of a differential vaccine. An 
extensive study of essential and non-essential parts of the viral genome has not been 
performed. The occurrence of natural variants with deletions in NSP2 indicated the 
purpose of NSPs as better targets in the designing of these kinds of vaccines (Fang et al., 
2004). 
Thus, it has become important to detect the T-cell epitopes and prepare a vector-based 
universal vaccine against PRRSV infection. In addition, it is necessary to construct 
vaccines that provide protection in both homologous and heterologous strains against 
PRRSV infection. 
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Chapter 3:  Materials and Methods 
General experimental design   
Figure 1 illustrates the experimental design used in this study to identify T-cell epitopes 
in PRRSV nonstructural proteins NSP 9, NSP 10 and NSP 11. To immunize the 
principal group against PRRSV FL-12 animals were initially infected with a single 
intramuscular injection of 10
6.5
 TCID50 of PRRSV FL-12 followed by two additional 
boosters of the same dose of PRRSV FL-12 given several weeks apart (see 
below)(Osorio et al., 2002). The first booster was administered emulsified in Freund’s 
complete adjuvant and the second was administered in incomplete Freund adjuvant. The 
screening tests for NSP 9 and NSP 10 were performed independent of each other at 
different time points and with different sets of pigs. To screen the NSP 9 peptides for 
their ability to stimulate a recall T-cell response, a total of sixteen 4-5 weeks old, 
Landrace x Large White were obtained from a PRRSV-free farm. Eight of those animals 
were immunized against PRRSV and the other eight were used as non-immune 
specificity controls. The first booster of the principal group was administered at 21 d.p.i 
and the second at 96 d.p.i. For NSP 10 screening, we used a total of six mixed-breed 
animals (same farm of origin, age, and genetic background as previous experiment, 4 
PRRSV-immunized principals and 2 uninfected controls). In this case the first booster 
was administered at 57 d.p.i and the second at 114 d.p.i. For both NSP 9 and NSP 10 
experiments, starting at day 7 d.p.i and for the entire length of immunization in each 
case, blood was collected weekly for the following assays: 1) confirmation of viral 
infection parameters (viremia, T-cell proliferation and IFN-γ secreting cells by ELISpot) 
and 2) testing the set of peptide pools as well as to confirm individual peptides. NSP 11 
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experiments were conducted using cryopreserved PBMCs isolated during NSP 10 
animal experiments.   
For, NSP 9, NSP 10 and NSP 11 experiments, the animal groups were separately housed 
in isolated bio-safety level 2 (BL-2) rooms to avoid cross-contamination. All the rooms 
were well-ventilated and supplied with standard diet ad libitum and proper waste 
disposal systems to avoid cross-contamination at all times.  
Virus strain  
To immunize the principal animals we used PRRSV FL-12 strain, which is a highly 
pathogenic PRRSV type II strain derived from the infectious clone of PRRSV NVSL 97-
7895 (Truong et al., 2004) (GenBank accession no. AY545985).  
Isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs)  
Ten ml of whole blood was collected in a 5mM heparin tube and PBMCs were isolated 
by density gradient centrifugation using the Lymphocyte Separation Media 
(Cellgro:Mediatech; cat # 25-072-CV) as previously described were washed using 
Hyclone RPMI media without 10% fetal bovine serum (FBS, SAFC; cat # 12003C). Then 
RPMI (10% FBS) was added to the isolated PBMCs obtained and the number of cells 
were counted using haemocytometer. Purified PBMCs were used for the T-cell 
proliferation assay. The purified PBMCs were also cryopreserved at a concentration of 
3x10
7 
viable cells/ml for ELISpot assay (Kreher et al., 2003). Pigs were bled once every 
week for testing the set of peptide pools as well as to confirm individual peptides. 
Cryopreservation of PBMCs was done at different time points including the first and 
second post booster doses. 
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Synthesis of PRRSV NSP 9, 10 and 11 synthetic peptides 
Three libraries of synthetic heptadeca peptides, with a 9 amino acid overlap, 
encompassing the entire sequence of NSP 9 (n=79, encompassing 646 aa), NSP 10 
(n=54, encompassing 441 aa) and NSP 11 (n=27, encompassing 223 aa) were obtained 
from NEO Peptide (Massachusetts) (Table 1). These peptides were used at a working 
concentration of 3mg/ml. Initially, these peptides were used in the form of peptide pools, 
each pool consisting of four overlapping 17-mer peptides located consecutively in the 
respective gene sequence (each peptide concentration 20ug/ml). Peptides from 
responding peptide pools were screened individually for the identification of all 
individual peptides eliciting immunogenic responses and hence, possessing potential for 
being T-cell epitopes. Twenty NSP 9, fourteen NSP 10 and seven NSP 11 peptide pools 
were prepared for the T-cell epitope mapping study (Table 1). 
 
T-cell proliferation Assay 
PBMCs were obtained after thorough centrifugation using Lymphocyte Separation Media 
(Cellgro:Mediatech; cat # 25-072-CV ). Cells were counted using a haemocytometer to 
estimate the number of PBMC used to perform the in vitro proliferation assay. Cells at a 
concentration of 4 x 10
6
cells/ml in RPMI medium with 10% FBS were used for the assay. 
A volume of 100µl cell suspensions was added to 100µl of synthetic peptides at a total 
concentration of 20µg/ml adjusted in RPMI (10% FBS) and placed in the wells of 96-
well U-bottom plate. Plates were incubated for 48 hours at 37°C in 5% CO2. Twenty 
microliters of [
3
H] Thymidine (corresponding to 1µCi per well; M P Bioquote) prepared 
in cloning medium was added into each well. The plate was incubated for 16 hours at 
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37°C. Cells were harvested using a PerkinElmer filtermate harvester. [
3
H] Thymidine 
incorporation was measured using a scintillation counter (PerkinElmer 1450 LSC). Two 
rounds of T-cell epitope screening were performed using this assay. The first round of 
screening was performed using the peptide pools and in the second round the positively 
responding (proliferating) peptide pools were checked for the T-cell proliferating activity 
induced by individual peptides. A peptide or pool was considered likely to contain a T-
cell epitope on the basis of stimulation index: the frequency of the proliferating cells in 
response to the peptides which is higher by ≥ 2 folds than the control cells (media only) 
alone (Vashisht et al., 2008). These experiments were repeated at least three times for all 
the three NSP 9 and NSP 10, except NSP 11 proteins. Ten microgram per ml of 
Concanavalin A was used as positive controls to validate the proliferation ability of the 
cells cultured with peptides in all cases (principals and control animals). 
 IFN-γ ELISpot Assay 
The PRRSV-specific IFN-γ ELISpot assay was previously studied and well established to 
detect T-cell epitopes (Diaz et al., 2009; Vashisht et al., 2008). Ninety-six well Millipore 
plates with PVDF membrane were selected to perform this assay (reference). To pre wet 
the membrane, 15μl 70% ethanol was added to each well and incubated at room 
temperature for 30 seconds. Primary antibody (porcine IFN-γ P2G10; BD Biosciences 
Pharmingen, 50μl at 10μg per ml concentration) was added to each well and incubated 
overnight at 4⁰C. The plate was washed six times with 0.05% sterile PBS-Tween20 and 
blocked with 150μl PBS-BSA 1%. It was then incubated at 4⁰C overnight. The plate was 
then washed with sterile PBS once and in each well 5 x 10
5 
PBMCs were added in media 
containing peptides selected from T-cell proliferation assay at 37⁰C overnight. Ten 
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microgram per ml Concanavalin A and PRRSV FL-12 strain (10
6.78 
TCID50 in infected 
cell homogenate) were used as positive controls to validate the gamma interferon 
responsiveness of the cells cultured with peptides. Plates were incubated at 37°C 
overnight. The plate was washed six times with PBS-Tween20 0.05% (sterile). Then, 
100μl secondary antibody (biotin P2C11; BD Biosciences Pharmingen) at 2μg per ml 
concentration was added to each well and incubated at 4⁰C overnight. The plate was 
washed six times with sterile PBS-Tween20 (0.05%) and incubated at 4⁰C for 45 minutes 
after adding 100μl streptavidin alkaline phosphatase (Southern Biotech; cat. # 7100-04) 
dissolved in PBS-BSA1% in 1:1000 dilutions. Subsequently, the plate was washed three 
times with sterile PBS-Tween20 (0.05%) followed by three washes with PBS. 100μl 
alkaline phosphatase substrate (Vector laboratories; cat. # SK-5300) was added to each 
well and kept at room temperature for 7-10 minutes. To stop further spot development, 
the plate was then washed extensively under running water to stop further spot 
development. The number of spot forming cells (SFCs) was counted using the C.T.L 
ELISpot machine. These experiments were repeated at least three times for NSP 9, NSP 
10 and NSP 11. This assay was performed using both cryopreserved cells and fresh 
PBMCs isolated at different time points and repeated at least three times. 
Determination of degree of conservation of epitopes  
ORF 1b nucleotide sequences from a diverse sample of type-II PRRSV isolates (n=34) 
obtained from NCBI database were translated and aligned using CLUSTALW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  Regions of ORF1b homologous to peptides 
containing candidate T-cell epitopes were identified. WebLogo bioinformatics tool was 
also used to show the graphical representation of the multiple sequence alignment 
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performed for all the 34 NA sequences (Crooks et al., 2004; Schneider and Stephens, 
1990). Moreover, ORF 1b nucleotide sequences from a diverse sample of type-II PRRSV 
isolates (n=65, Genbank accession numbers pending) were translated, aligned using 
MUSCLE (Edgar, 2004) and visualized using JALVIEW(Waterhouse et al., 2009).  
Regions of ORF1b homologous to peptides containing candidate T-cell epitopes were 
identified and the proportion of PRRSV isolates containing sequences identical to those 
of the peptide determined as an indicator of conservation within this sample of PRRSV 
isolates.  
Bioinformatics approach  
All the three proteins of the PRRSV, namely NSP 9, NSP 10 and NSP 11 were analyzed 
for the MHC class I and MHC class II-peptide binding prediction tools.  BIMAS was 
used to analyze CTL epitope by binding to the selected overlapping peptides against 33 
human alleles present in its database (Parker et al., 1994). The binding affinity (T1/2 
value) depends on the half-time of dissociation of the β2 micro globulin from HLA. A 
cutoff T1/2 value of ≥ 100 minutes as well as <100 minutes were selected for analysis. 
SYFPEITHI (Rammensee et al., 1999) and PROPRED (Singh and Raghava, 2001) are 
the other two algorithms used to identify CTL and class II HLA alleles, respectively. The 
optimal value for SYFPEITHI (Rammensee et al., 1999)  is ≥15 and for PROPRED 
(Singh and Raghava, 2001) the threshold percent is recommended in between 1-3%. The 
PROPRED threshold percentage was altered differently to check the binding affinity of 
the peptides to the MHC class II alleles. 
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Chapter 4: Results 
 Screening of PRRSV NSP 9 and NSP 10 for T-cell epitopes using T-cell 
proliferation assay 
Twenty peptide pools from NSP 9 were used for the first round of peptide screening 
(figure 2). Based on the criteria described in the materials and methods for analysis of 
functional assays, four out of twenty NSP 9 peptide pools encompassing amino acid 
positions 103-143, 135-175, 199-239 and 519-559 were identified with stimulation 
indices at least twice background (Table 2a). As a result of the T-cell proliferation assay 
of the individual peptides present in those four NSP 9 peptide pools (figure 3a), it was 
found that four peptides beginning with amino acid positions 119, 151, 207 and 519 
elicited positive proliferation results (Table 3).  
Fourteen peptide pools from NSP 10 were used for the first round of peptide screening 
(figure 2b). Two out of fourteen NSP 10 peptide pools, encompassing amino acid 
positions 129-169 and 193-233, were identified which elicited positive stimulation 
indices (Table 2). As a result of the T-cell proliferation assay of the individual peptides 
present in those two NSP 10 peptide pools (figure 3b it was found that two peptides 
encompassing amino acid positions 209-225 and 217-233  respectively exhibited positive 
stimulation indices (Table 3).  
Seven peptide pools from NSP 11 were used for the first round of peptide screening 
(figure 2c). Two out of seven peptide pools, encompassing amino acid positions 1-41 and 
33-73, respectively exhibited positive stimulation indices (Table 3). The second round of 
screening was not performed for NSP 11 due to limited number of cryopreserved vials 
32 
 
which could be used for one more set of experiment. We used those cryopreserved 
PBMCs for IFN-γ secreting ELISpot assay to detect the immunogenic epitopes present in 
the NSP 11 PRRSV protein. Another reason to directly opt for this immunogenic assay 
was that we have to detect T-cell epitopes from eight peptides present in those two 
peptide pools obtained in the first round of screening. Therefore, the one set of 
cryopreserved PBMCs were directly used for ELISpot assay, particularly in the case of 
NSP 11. 
 None of the PBMCs isolated from the control pigs responded to the specific peptides 
obtained after two rounds of T-cell peptide screening. All the above experiments were 
performed using fresh PBMCs except NSP 11 which was performed using cryopreserved 
PBMCs.   
 
Identification of PRRSV immunogenic individual peptides from NSP 9, NSP 10 and 
NSP 11 
Table 4 provides a summary of the results obtained from cryopreserved PBMCs 
stimulated with NSP 9, 10 and 11 peptides inducing IFN-γ. Out of 4 NSP 9 peptides 
tested (those that gave a positive response in the lymphoproliferation assay), 2 peptides 
at amino acid position 119-135 and 151-167 (KEEIALSAQIIQACDIR and 
VRGNPERVKGVLQNTRF) showed specific immunospots as compared with their non-
immunized counterparts (Table 4). During this analysis, the remaining two peptides did 
not stimulate IFN-γ response in PBMC populations. In case of NSP 10, both the 
individual peptides stimulated proliferation of IFN-γ secreting cells at different time 
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points (Table 4). The peptide at amino acid position 209-225 (VRILAGGWCPGKNSFLD) 
showed significant increase in IFN-γ ELISpot positive cells following stimulation. The 
peptide at amino acid position 217-233 (CPGKNSFLDEAAYCNHL) was able to show 
specific immunospots following the second booster dose (121 days post-initial infection 
and 7 days after second booster). Three out of eight NSP 11 peptides showed significant 
IFN-γ secretion. These peptides are located at amino acid position 1-17 
(GSSSPLPKVAHNLGFYF), 9-25 (VAHNLGFYFSPDLTQFA) and 57-73 
(VHKYSRACIGAGYMVGP) (Table 4). 
 
Conservation of PRRSV NSP 9, NSP 10 and NSP 11 peptides identified throughout 
North American PRRSV Type-II strains 
Thirty-four sequences of North American PRRSV isolates obtained from worldwide 
locations (source: NCBI databank) were aligned using Clustal W analytical tool. Figure 4 
illustrates the conservation of these identified immunodominant peptides obtained from 
NSP 9, NSP 10 and NSP 11 of PRRSV. NSP 9 peptide sequence 
KEEIALSAQIIQACDIR of FL-12 strain at amino acid position 119 was conserved 
throughout the North American isolates (figure 4a,b). Two alterations were found at 
amino acid positions 122, 126 and 133 (valine for isoleucine, valine/Methylamine for 
alanine and aspartic acid to glycine). In case of peptide sequence 
VRGNPERVKGVLQNTRF, six alterations were found at amino acid position 151 (valine 
by isoleucine), 154 (asparagine by aspartic acid), 156 (glutamic acid to aspartic acid), 158 
(valine by alanine), 161 (valine by leucine) and 163 (glutamine by lysine)(figure 4a). 
Conservation variation was also noted in NSP 10 peptide sequence 
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VRILAGGWCPGKNSFLD at amino acid position 211 where isoleucine was replaced by 
threonine. In addition, a unique non-conserved region was also noticed in NSP 11 peptide 
sequence GSSSPLPKVAHNLGFYF where tyrosine was replaced by histidine at amino 
acid position number 16. Similarly, in case of the other two peptide sequences of NSP 11 
amino acid replacement could also be seen (figure 4a). A graphical representation of the 
T-cell epitopes from PRRSV NSPs 9, 10 and 11 showing 90-95% conservation pattern 
among 34 NA sequences of PRRSV has been represented in figure 4b. 
 
Table 6 illustrates the conservation of these identified NSP 9, NSP 10 and NSP 11 
peptides in a sample of diverse PRRSV field isolates. The NSP 9 peptide sequence of FL-
12 strain at amino acid position 119 was conserved in 22 % of the strains throughout the 
North American isolates (Table 6). Unlike, the second epitope at amino acid position 151 
found in NSP 9 sequence was conserved in 84% of the 65 NA-PRRSV sequences 
analyzed. In case of NSP 10, two T-cell epitopes at amino acid positions 209 and 217 
were found to be 95% and 96% conserved, respectively (Table 6). Similarly, NSP 11 T-
cell epitopes at amino acid positions 1, 9 and 57 were found to be 96%, 92% and 20% 
conserved, respectively (Table 6). 
 
 
Binding specificity of peptides to HLA class I and II molecules predicted by various 
algorithms 
 
 
The HLA-peptide binding analysis of PRRSV NSPs 9, 10 and 11 have been carried out at 
various binding affinities (BIMAS-T1/21-100 minutes; SYFPEITHI-score ≥15 and 
PROPRED threshold percentage >3%). The peptides showing both proliferation and 
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immunogenicity properties were selected for such an analysis and have been shown in the 
Table 5. It was found that one out of two NSP 9 peptides, one out of two NSP 10 peptides 
and two out of three NSP 11 peptides were able to show good binding affinity in all the 
three algorithms used. Three peptides showed distinct results by not binding to any of the 
HLAs present in at least one of the three different algorithms used in this study. NSP 9 
peptide at amino acid position 119 could only bind MHC alleles at a low T1/2 value (1-50 
minutes). It showed, however, good HLA binding affinity by using SYFPEITHI as well 
as PROPRED at their desired optimum values. Similarly, binding specificity of NSP 10 
peptide at amino acid position 217 to MHC class II alleles could be seen only above the 
threshold value (10%). NSP 11 peptide at amino acid position 1 was unable to bind to 
both BIMAS and PROPRED at their proposed optimum values. Moreover, it showed 
binding affinity to the MHC class I and II alleles at a lower T1/2 value (1-20 minutes) in 
BIMAS and 7% threshold value using PROPRED (Table 5). Altogether, these results 
suggest a good correlation link between the bioinformatics approach and functional 
assays performed.  
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Chapter 5: Discussion 
Both neutralizing antibodies and CMI contribute towards the establishment of PRRSV 
protective immunity (Kimman et al., 2009; Lopez and Osorio, 2004). While the 
mechanisms and viral determinants of protective immunity against PRRSV are 
incompletely characterized, protection likely results from recognition of viral epitopes by 
both antibodies and T-cells. Identification of T-cell epitopes mediating heterologous 
protection, and the nature of variation in those epitopes will directly enhance prediction 
of vaccine efficacy and guide the rational design or selection of broadly protective 
vaccines through estimation of the optimal composition of epitopes for the formulation of 
vaccines efficacious against the majority of PRRSV strains.  This would represent a 
significant advance in the control of PRRSV. Our present report deals with functional T-
cell epitope mapping focused on selected nonstructural PRRSV proteins. These NSPs 
constitute fundamental, highly conserved proteins used for the early stages of viral 
replication. 
The strictly functional approach that we followed in this study has been based on two 
bonafide CMI assays: lymphocyte proliferation and frequency of IFN-γ secreting cells. It 
has been reported that lymphocyte proliferation from PRRSV-infected pigs can be 
detected starting at 4 weeks PI (Bautista and Molitor, 1997; Lopez Fuertes et al., 1999). 
Those proliferating cells can also secrete IFN-γ and hence, T-cell response measured by 
IFN-γ secreting cell frequency has been shown to be central in clearing viral infections 
(Callan et al., 1996; Gruters et al., 2002; Martin et al., 2004; Riddell et al., 1991; Riddell 
et al., 1992).   
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The emphasis on PRRSV T-cell epitope research and identification has centered, until 
now, exclusively on important structural components of this virus. Several papers have 
been published suggesting the existence of T-cell epitopes in GP5 (Diaz et al., 2009; 
Vashisht et al., 2008), GP4 (Diaz et al., 2009), N (Diaz et al., 2009) and M protein (Wang 
et al., 2011). In our case we selected three PRRSV NSPs ( NSP 9,the RdRp, NSP 10, a 
helicase and NSP 11, a endonuclease) based on their functional role in viral replication 
and virulence, (Fang and Snijder, 2010). NSP 9, NSP 10 and NSP 11 seem to be highly 
conserved, being consistent throughout the North American PRRSV strains, thus 
constituting good tentative candidates for T-cell epitope mapping to provide cross-
protection immunity against PRRSV infection. 
Our present report deals with functional epitope mapping focused on selected 
nonstructural PRRSV proteins. These NSPs constitute fundamental, highly conserved 
proteins used for the early stages of viral replication. The conservation of the identified 
epitopes was investigated by aligning amino acid sequences of the NSP 9, NSP 10 and 
NSP 11 of North American genotype-II PRRSV strains. Considering the above points, 
our data suggests that T-cell epitope amino acid sequence identity is 91% in NSP 9 
(amino acid position 119), 79% in NSP 9 (amino acid position 151), 100% in NSP 10 
(amino acid position 209 and 217), 94% in NSP 11 (amino acid position 1), 88% in NSP 
11 (amino acid position 9) and 79% in NSP 11 (amino acid position 57) (figure 4). Also, 
the conservation of the identified epitopes was investigated by aligning sixty-five amino 
acid sequences of the NSP 9, NSP 10 and NSP 11 of North American genotype-II 
PRRSV strains. Considering the above points, our data suggests that the T-cell epitopes 
herein identified range in amino acid sequence identity among 22% in NSP9 (amino acid 
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position 119), 84% in NSP 9 (amino acid position 151), 95% in NSP 10 (amino acid 
position 209), 97% in NSP 10 (amino acid position 217), 96% in NSP 11 (amino acid 
position 1), 92% in NSP 11 (amino acid position 9) and 20% in NSP 11 (amino acid 
position 57) (Table 6). From these results, we can confirm that even though these 
epitopes are not absolutely conserved, they remain conserved in most of the North 
American isolates except for a few mutations in a very low percentage of the strains.   
The virus used in our study is the PRRSV FL-12, a highly pathogenic strain derived from 
an infectious clone constructed upon parental strain NVSL 97-7895, which belongs to 
North American type-II genotype (Truong et al., 2004).  Pigs were infected with the 
PRRV FL-12 and PBMCs obtained from those pigs were used to analyze synthetic 
peptides from NSP 9, NSP 10 and NSP 11. From the present data we cannot infer which 
type of cells, within the reacting PBMCs (i.e. CD4+ vs. CD8+ T-cells) are actually 
responding to these peptides. Future studies oriented towards such identification would 
contribute to a more complete understanding on the specific mechanisms on which the 
development of future vaccines should rely. 
An important aspect of this preliminary T-cell epitope identification is the immunogenic 
character of these epitopes, which has been confirmed by ELISpot. In most cases, the 
ELISpot results (Table 4) were obtained only after the first or second booster inoculations 
following the initial infection with PRRSV FL-12. It has been shown that the amount of 
IFN-γ produced per T-cell against PRRSV is low during the first few weeks after 
immunization or infection with PRRSV, although it gradually increases significantly after 
3-4 months post-vaccination (Meier et al., 2003; Zuckermann et al., 2007). Evidence for a 
role of CMI in protective immunity against PRRSV has been reported by studies in which 
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a correlation was found between the IFN-γ response and protective immunity (Meier et 
al., 2003; Zuckermann et al., 2007).  We have previously reported that the IFN-γ 
response can be used as an indicator of protective immunity and emphasized that in 
certain cases the post-challenge recall kinetics of serum neutralizing antibodies does not 
correlate with protection(Zuckermann et al., 2007). Similarly, others have concluded that 
the presence of virus-specific IFN-γ-secreting T-cell response indicates that vaccination 
has elicited protective immunity (Diaz et al., 2006; Martelli et al., 2009).  
Overall the IFN-γ response observed with these two sets of peptides would represent a 
recall response mediated by PRRSV-specific memory T-cells (Vashisht et al., 2008). The 
peptides were synthesized with high purity which explains that the strong reactivity to 
these peptides was not due to any kind of contamination; rather, it represents PRRSV 
NSP 9, NSP 10 and NSP 11 immunogenic epitopes. The mean ± standard deviation 
criterion provides a positive feedback for selecting the peptides with certain cut-off 
values thereby restricting the selection of the immunodominant T-cell epitopes. 
Unpublished data from our laboratory have shown that cryopreserved PBMCs and 
PBMCs extracted from fresh blood exhibit similar activity in ELISpot assays. Although 
the magnitude of the immune response was different with different peptides, the 
quantitative results remain truly identical. The different PBMCs used for the comparative 
ELISpot studies were obtained during the same course of experiments reported here. The 
PBMCs were cryopreserved at different time points and the results shown in Table 4 are 
a compiled version of all of them. A thorough and consistent report has been obtained 
throughout the ELISpot experimental analysis.  
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The reports of PRRSV T-cell epitopes existing in the literature include different 
approaches ranging from primarily bioinformatics discovery using algorithms for 
prediction of T-cell epitopes (Diaz et al., 2009) to those that, like the one herein 
described, predominantly map T-cell epitopes by scanning of overlapping peptides along 
the protein sequence and assessing their activity in functional assays (Vashisht et al., 
2008; Wang et al., 2011). 
It could be argued that false positive and negative results might occur due to the usage of 
elevated peptide concentrations to stimulate PBMCs in our experimental study 
(10µg/ml).  However, the concentration we used is well within the range of 
recommended peptide concentration for T-cell epitope mapping and is consistent with 
those commonly used and reported in recent literature (Assarsson et al., 2008; Dow et al., 
2008; Gerner et al., 2009; Haghighi et al., 2009; Streeck et al., 2009; Wulf et al., 2009).  
False positive peptides are readily excluded by subsequent confirmatory tests.  False 
negatives are reduced by designing pools such that each peptide is contained in more than 
one pool, minimizing the probability that highly avid peptides will outcompete any 
individual peptide (Hoffmeister et al., 2003). 
ELISpot assay has proved to be a cost-effective technique to detect T-cell epitopes in 
various viral diseases (Streeck et al., 2009).  It should be born in mind, however, that the 
relationship between the SLA class I and II haplotypes, and the IFN-γ secretion against 
PRRSV has also not yet been characterized so far. Future studies should focus on the 
characterization, not only of the type of T-cell prevailing in this epitope stimulation, but 
also on the characterization of the SLA haplotypes involved in this response. It should be 
noted that the response that we measured against individual peptides has been observed, 
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in the best case in ≤ 50 % of the animals (Tables 3 and 4). This is might be expected, 
given the known polymorphism of the SLA and the fact that pigs used in these 
experiments, though from a similar genetic background, were of unknown SLA 
haplotypes.     
Taken together, we have identified T-cell epitopes present in the NSP 9, NSP 10 and NSP 
11 proteins of PRRSV based on their functional and structural constraints. These proteins 
were able to show significant T-cell proliferation as well as IFN-γ secretion. The degree 
of conservation of these epitopes suggests that they may be highly useful in the rational 
design of broadly efficacious vaccines against PRRSV.  
 
 
 
 
 
 
 
Table1. Name of the peptide pools and individual peptides used for T-cell 
proliferation and ELISpot assays. 
Peptide pool no. I II III IV V VI VII VIII IX X 
 
 
 
7-23 39-55 71-87 103-119 135-151 167-183 199-215 231-247 263-279 295-311 
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15-31 47-63 79-95 111-127 143-159 175-191 207-223 239-255 271-287 303-319 
 
23-39 55-71 87-103 119-135 151-167 183-199 215-231 247-263 279-295 311-327 
 
31-47 63-79 95-111 127-143 159-175 191-207 223-239 255-271 287-303 319-335 
 
XI XII XIII XIV XV XVI XVII XVIII XIX XX 
 
327-343 359-375 391-407 423-439 455-471 487-503 519-535 551-567 583-599 615-631 
 
335-351 367-383 399-415 431-447 463-479 495-511 527-543 559-575 591-607 623-639 
 
343-359 375-391 407-423 439-455 471-487 503-519 535-551 567-583 599-615 631-646 
 
351-367 383-399 415-431 447-463 479-495 511-527 543-559 575-591 607-623 
 
           
Peptide pool no. I II III IV V VI VII VIII IX X 
 
 
 
1-17 33-49 65-81 97-113 129-145 161-177 193-209 225-241 257-273 289-305 
 
9-25 41-57 73-89 105-121 137-153 169-185 201-217 233-249 265-281 297-313 
 
17-33 49-65 81-97 113-129 145-161 177-193 209-225 241-257 273-289 305-321 
 
25-41 57-73 89-105 121-137 153-169 185-201 217-233 249-265 281-297 313-329 
 
XI XII XIII XIV 
      
 
321-337 353-369 385-401 417-433 
      
 
329-345 361-377 393-409 425-441 
      
 
337-353 369-385 401-417 
       
 
345-361 377-393 409-425 
       
           
Peptide pool no. I II III IV V VI VII 
    
 
 
1-17 33-49 65-81 97-113 129-145 161-177 193-209 
   
 
9-25 41-57 73-89 105-123 137-153 169-185 201-217 
   
 
17-33 49-65 81-97 113-129 145-161 177-193 209-225 
   
 
25-41 57-73 89-105 121-137 153-169 185-201 
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Notes: Pigs in the principal group were inoculated with PRRSV FL-12 and blood samples 
were collected starting at 7 d.p.i. The results shown here is the average of the PBMCs 
collected on 14 d.p.i., 21 d.p.i. and 28 d.p.i. This table shows the nine amino acid 
overlapping sequence length of peptide pools identified from PRRSV NSP 9, 10 and 11 
at their respective amino acid positions after the first round of T-cell epitope mapping. 
The number of responding pigs is the immunized animals whose PBMC exhibited a 
peptide-specific proliferation with a stimulation index ≥ 2 along with a zero background 
response. The response to the peptides had to be ≥ 2 than the proliferated cells of non-
immunized control pigs to be considered positive. None of the PBMCs samples isolated 
from the control pigs responded to the peptides pools herein shown.  
 
 
  
 
 
 
Table 2. Identification of peptide pools using lymphoproliferative [H
3
] incorporation assay. 
 
protein 
name 
 
peptide 
pool no. overlapping aa sequence in a peptide pool 
no. of resp. 
pigs for each 
peptide pool 
NSP 9 IV NTGIDGTLWDFEAEATKEEIALSAQIIQACDIRRGDAPEIG 3\8 
 
V RRGDAPEIGLPYKLYPVRGNPERVKGVLQNTRFGDIPYKTP  1\8 
 
VII RSVLATTMPSGFELYVPTIPASVLDYLDSRPDCPKQLTEHG 1\8 
 
XVII ESPTMPNYHWWVEHLNLMLGFQTDPKKTAITDSPSFLGCRI 1\8 
NSP 10 V CKEINMVAVASNVLRSRFIIGPPGAGKTYWLLQQVQDGDVI 4\4 
 
VII AGTTLQFPAPSRTGPWVRILAGGWCPGKNSFLDEAAYCNHL 3\4 
NSP 11 I              GSSSPLPKVAHNLGFYFSPDLTQFAKLPVELAPHWPVVTTQ 1\4 
 
II PHWPVVTTQNNEKWPDRLVASLRPVHKYSRACIGAGYMVGP    1\4 
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Notes: Pigs in the principal group were inoculated with PRRSV FL-12 and blood samples 
were collected 7 days post first booster dose (boosters were applied at 21 d.p.i for NSP 9 
study and at 57 d.p.i for NSP 10 study). This table shows the heptadecamer sequence 
length of the individual peptides identified from PRRSV NSP 9 and 10 at their respective 
amino acid positions after the second round of T-cell epitope mapping. The number of 
responding pigs is the immunized animals whose PBMC exhibited a peptide-specific 
proliferation with a stimulation index ≥ 2 along with a zero background response. The 
response to the peptides had to be ≥ 2 than the proliferated cells of non-immunized pigs 
to be considered positive. None of the PBMCs samples isolated from the non-immunized 
control pigs responded to any of these individual peptides. 
 
 
 
 
 
Table 3. Identification of heptadecamer PRRSV peptides likely to contain of NSP 9 and 
NSP 10 epitopes.  
 
protein name peptide name peptide sequence 
no. of resp. pigs for 
each individual 
peptide 
 NSP 9 119-135 KEEIALSAQIIQACDIR 4\8 
 
 
151-167 VRGNPERVKGVLQNTRF 2\8 
 
 
207-223 PSGFELYVPTIPASVLD 1\8 
 
 
519-535 ESPTMPNYHWWVEHLNL 2\8 
 
     NSP 10 209-225 VRILAGGWCPGKNSFLD 2\4 
 
 
217-233 CPGKNSFLDEAAYCNHL 2\4 
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Notes: Pigs were initially infected with PRRSV FL-12 and subsequently were 
administered two additional boosters (at 21 d.p.i and 96 d.p.i for the NSP 9 experiment, 
and at 57 and 114 d.p.i for the NSP 10 and NSP 11 experiments. The ELISpot results 
shown here is the compilation of data obtained from the interferon response from the 
PBMCs cryopreserved at different time points post first and second booster doses. The 
ELISpot experiments for each protein were performed independently. 
a
Max.resp: number of IFN-producing cells detected in PBMC from the highest 
responder pig among all 2 PBMC samples tested. 
b
Tot.resp: sum of all of the IFN-producing cells (minus background) detected in 
the 2 individually tested PBMC samples. 
c
Avg. resp: sum of all the IFN-producing cells (minus background) detected in the 
2 PBMC samples tested divided by 2, the number of pigs tested. 
d
No. Resp. pigs: number of pigs exhibiting a frequency of peptide-specific IFN-γ 
secreting cells with a stimulation index ≥ 2 than the cells only. If background 
response was zero the response to the peptide had to be ≥2 to be considered 
positive. 
e
Avg Resp pigs: average of the peptide-specific IFN-specific IFN-response 
(minus background) of all the pigs exhibiting a response to the individual peptide.  
f
Mean±Std.D: mean ± standard deviation of the values shown for each of the four 
T-cell peptide candidate for each of the selection criteria were concluded to 
contain an immunodominant peptide (Vashisht et al., 2008).  
Peptide sequences in bold represent the positive peptides which showed maximum IFN-γ 
secretion. Controls used in this assay were: concanavalin A (positive control), FL-12 
infected cell homogenates (positive control) and PBMCs only, without peptide (negative 
control). None of these peptides reacted with the PBMCs of the non-immunized control 
pigs (mean ± std.dev. = 0±3).  
 
Table 4. T-cell epitopes in PRRSV NSP 9, NSP 10 and NSP 11 identified by the IFN-γ induction 
criteria. 
 
Protein 
name 
aa 
position peptide sequence 
a
max. 
resp 
b
tot. resp 
c
avg. 
resp 
d
no. 
resp. 
pigs 
e
avg. resp 
pigs 
NSP 9 119-135 KEEIALSAQIIQACDIR 8 10.6 1.7 2\8 12.8 
NSP 9 151-167 VRGNPERVKGVLQNTRF 8. 6 5.3 0.8 2\8 8.5 
NSP 9
 
207-223 PSGFELYVPTIPASVLD 3.7 9 1.5 1\8 0.7 
NSP 9
 
519-535 ESPTMPNYHWWVEHLNL 2.7 3 0.5 2\8 4.7 
        NSP 10 209-225 VRILAGGWCPGKNSFLD 7.3 4.3 1.0 1\4 14 
NSP 10 217-233 CPGKNSFLDEAAYCNHL 27.3 33.9 8.4 2\4 21.2 
        NSP 11 1-17 GSSSPLPKVAHNLGFYF 37.33 63.99 21.33 1\4 65 
NSP 11 9-25 VAHNLGFYFSPDLTQFA 40 48.99 16.33 1\4 67.67 
NSP 11 57-73 VHKYSRACIGAGYMVGP 39.66 63.33 21.11 1\4 65.33 
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Table 5. Feasibility of PRRSV nonstructural proteins to HLA using various peptide 
prediction tools at different threshold values. 
Note: Plus sign represents the different HLA alleles bound to T-cell epitopes obtained 
from PRRSV NSPs 9, 10 and 11. ‘+’=one allele; ‘++’=2-3 alleles; ‘+++’=3 or more 
alleles; ‘no’=no alleles binding. 
 
 
Protein 
name 
aa 
posn. BIMAS SYFPEITHI PROPRED 
  
At     low 
T1/2(<100) At T1/2(≥100) score ≥15 
Threshold 
(1-3%) 
Above 
threshold 
NSP9 119 +++ no +++ + - 
       
 
151 +++ ++ +++ +++ - 
       NSP10 209 +++ + +++ +++ - 
       
 
217 +++ + ++ no + 
       NSP11 1 +++ no +++ no + 
       
 
9 +++ ++ +++ +++ - 
       
 
57 +++ ++ +++ +++ - 
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Table 6. Conserved T-cell epitopes in NSP 9, NSP 10 and NSP 11. 
 
 
Sequence Count  *Proportion 
NSP 9 (119-135) 
  KEEVALSAQIIQACDIR 28 0.43 
KEEIALSAQIIQACDIR 14 0.22 
KEEIALSAQIIQACGIR 8 0.12 
KEEIALSAQIIQACDMR 5 0.08 
KEEVALSAQIIQACDMR 2 0.03 
KEEVALSAQIIQACGIR 2 0.03 
KEEIELSAQIIQACGIR 2 0.03 
KEEIALSTQIIQACDIR 1 0.02 
KEEIALSAQIIQACSIR 1 0.02 
KEEIALSEQIIQACDIR 1 0.02 
KEEVALSTQIIQACDIR 1 0.02 
NSP 9 (151-167) 
  VRGNPERVKGVLQNTRF 55 0.8461538 
IRGNPERVKGVLRNTRF 1 0.0153846 
VRDNPERVKGVLKNTRF 1 0.0153846 
VRGDPERVKGVLKNTRF  1 0.0153846 
VRGNPERARGVLMNTRF 1 0.0153846 
VRGNPERVNGVLQNTRF 2 0.0307692 
VRGNPERVKGVLRNTRF 3 0.0461538 
VRGNPERVKGVLKNTRF 1 0.0153846 
NSP 10 (209-225) 
  VRILAGGWCPGKNSFLD 62 0.9538462 
VRILAGGWCPGRNSFLD 2 0.0307692 
VRILAGRWCPGKNSFLD 1 0.0153846 
NSP 10 (217-233) 
  CPGKNSFLDEAAYCNHL 63 0.9692308 
CPGRNSFLDEAAYCNHL 2 0.0307692 
NSP 11 (1-17) 
  GSSSPLPKVAHNLGFYF 63 0.96923077 
NSP 11 (9-25) 
  VAHNLGFYFSPDLTQFA 60 0.92307692 
VAHNLGFYFSPDLIQFA 2 0.03076923 
VAHNLGFYFSPDLAQFA 1 0.01538462 
NSP 11 (57-73) 
  VHKYSRACIGAGYMVGP 13 0.2 
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IHKYSRACIGAGYMVGP 44 0.67692308 
IHKHSRACVGAGYMVGP 2 0.03076923 
IHKHSRACIGAGYMVGP 2 0.03076923 
IHKYSRACVGAGYMVGP 1 0.01538462 
IHNYSRACIGAGYMVGP 1 0.01538462 
 
Notes: Sequences in bold define the T-cell epitopes obtained in our study after stringent 
categorization of the heptadecamer peptides present in NSP 9, NSP 10 and NSP 11. Other 
heptadecamer sequences were considered from various other PRRSV isolates among the 
65 sequences aligned. The count number denotes the number of identical sequences out 
of 65 sequences aligned using JALVIEW. *Proportion of the sequence represents the 
conservation of those T-cell epitopes by applying the following formula: 
 no. of count of similar sequences/total no. of sequences used for multiple alignment. 
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Figure 1 
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Figure 2 
(a)
 
(b) 
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(c) 
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Figure 3 
(a) 
 
(b)  
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Figure 4 
(a) 
 
Notes: Sequence accession number in bold red defines the PRRSV virulent strain (FL-12) 
used in our study to determine T-cell epitopes after stringent categorization of the 
heptadecamer peptides present in NSP 9, NSP 10 and NSP 11. Other heptadecamer 
sequences were considered from various other NA-PRRSV isolates among the 34 
sequences aligned. The bold letters in red denotes the amino acid variations observed in 
the different PRRSV sequences used for the multiple sequence alignment. 
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(b) 
 
Note: Graphical representation showing conservation of the seven T-cell epitopes 
obtained from NSP 9, 10 and 11 by performing multiple sequence alignment via weblogo 
bioinformatics tool. The amino acids which reach 4 bits on the y-scale are highly 
conserved whereas the one which are lower than that are conserved with a lower 
percentage. 
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